GALE Stock Analysis: Galenica Sante | SW
Medical Distribution | SW, Switzerland | Market Cap: 4.390m CHF | 12M Return: 5% | CH0360674466 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.92M
Warnings
Tailwinds
No distinct edge detected
Seasonality 9.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Galenica AG is a Swiss healthcare services company operating through two main segments: Products & Care and Logistics & IT. The Products & Care segment runs a network of retail pharmacies under the Amavita, Sun Store, and Coop Vitality brands, alongside a specialty pharmacy (mediservice) that supplies medications for at-home treatment, and provides laboratory medicine, pathology, and personalized diagnostic services. The Logistics & IT segment supplies pre-wholesale services-including storage, distribution, and debt collection-to pharmaceutical and healthcare companies, while also offering master data systems, pharmacy management software, and pharmaceutical product information, and delivering medicines to pharmacies, drugstores, doctors, hospitals, and care homes.
The company was founded in 1927 and is headquartered in Bern, Switzerland. As a Health Care Distributor in the GICS classification, Galenica sits at the intersection of pharmacy retail and pharmaceutical wholesale logistics, both of which operate within Switzerlands strictly regulated healthcare market, where pharmacy ownership rules and cantonal-level oversight shape competitive dynamics for retail chains and distribution providers.
- Swiss pharmacy network expansion lifts Products & Care sales
- mediservice specialty pharmacy grows on chronic disease demand
- Online pharmacy competition pressures Swiss drug retail margins
| Net Income: 159.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -3.11 > 1.0 |
| NWC/Revenue: 1.70% < 20% (prev 6.07%; Δ -4.38% < -1%) |
| CFO/TA 0.08 > 3% & CFO 251.6m > Net Income 159.2m |
| Net Debt (1.32b) to EBITDA (349.0m): 3.77 < 3 |
| Current Ratio: 1.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.9m) vs 12m ago -0.08% < -2% |
| Gross Margin: 9.86% > 18% (prev 9.74%; Δ 0.12% > 0.5%) |
| Asset Turnover: 133.9% > 50% (prev 131.1%; Δ 2.80% > 0%) |
| Interest Coverage Ratio: 13.89 > 6 (EBIT TTM 204.3m / Interest Expense TTM 14.7m) |
| A: 0.02 (Total Current Assets 1.12b - Total Current Liabilities 1.04b) / Total Assets 3.32b |
| B: 0.43 (Retained Earnings 1.42b / Total Assets 3.32b) |
| C: 0.06 (EBIT TTM 204.3m / Avg Total Assets 3.19b) |
| D: 0.74 (Book Value of Equity 1.41b / Total Liabilities 1.91b) |
| Altman-Z'' = 2.75 = A |
| DSRI: 0.95 (Receivables 629.5m/623.2m, Revenue 4.28b/4.02b) |
| GMI: 0.99 (GM 9.74% / 9.86%) |
| AQI: 1.07 (AQ_t 0.52 / AQ_t-1 0.49) |
| SGI: 1.06 (Revenue 4.28b / 4.02b) |
| TATA: -0.03 (NI 159.2m - CFO 251.6m) / TA 3.32b) |
| Beneish M = -3.00 (Cap -4..+1) = A |
As of October 31, 2026, the stock is trading at CHF 87.45 with a total of 65,267 shares traded. Over the past week, the price has changed by -2.35%, over one month by +6.97%, over three months by -0.91% and over the past year by +5.04%.
Current recommended Stop Loss: 85.50 (which is 2.2% or 1.4 ATR below the current price).
Galenica Sante has no consensus analysts rating.
P/E Trailing = 27.2755
P/E Forward = 20.79
P/S = 1.0243
P/B = 2.8898
Revenue TTM = 4.28b CHF
EBIT TTM = 204.3m CHF
EBITDA TTM = 349.0m CHF
Long Term Debt = 601.5m CHF (from longTermDebt, last fiscal year)
Short Term Debt = 344.1m CHF (from shortTermDebt, last quarter)
Debt = 1.36b CHF (from shortLongTermDebtTotal, last quarter) + Leases 229.6m
Net Debt = 1.32b CHF (calculated: Debt 1.36b - CCE 39.6m)
Enterprise Value = 5.71b CHF (4.39b + Debt 1.36b - CCE 39.6m)
Interest Coverage Ratio = 13.89 (Ebit TTM 204.3m / Interest Expense TTM 14.7m)
EV/FCF = 25.94x (Enterprise Value 5.71b / FCF TTM 220.0m)
FCF Yield = 3.86% (FCF TTM 220.0m / Enterprise Value 5.71b)
FCF Margin = 5.14% (FCF TTM 220.0m / Revenue TTM 4.28b)
Net Margin = 3.72% (Net Income TTM 159.2m / Revenue TTM 4.28b)
Gross Margin = 9.86% ((Revenue TTM 4.28b - Cost of Revenue TTM 3.86b) / Revenue TTM)
Gross Margin QoQ = 9.07% (prev 10.63%)
Tobins Q-Ratio = 1.72 (Enterprise Value 5.71b / Total Assets 3.32b)
Interest Expense / Debt = 1.08% (Interest Expense 14.7m / Debt 1.36b)
Taxrate = 17.18% (33.7m / 196.2m)
NOPAT = 169.2m (EBIT 204.3m * (1 - 17.18%))
Current Ratio = 1.07 (Total Current Assets 1.12b / Total Current Liabilities 1.04b)
Debt / Equity = 0.96 (Debt 1.36b / totalStockholderEquity, last quarter 1.41b)
Debt / EBITDA = 3.77 (Net Debt 1.32b / EBITDA 349.0m)
Debt / FCF = 5.99 (Net Debt 1.32b / FCF TTM 220.0m)
Total Stockholder Equity = 1.47b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.98% (Net Income 159.2m / Total Assets 3.32b)
RoE = 10.82% (Net Income TTM 159.2m / Total Stockholder Equity 1.47b)
RoCE = 9.86% (EBIT 204.3m / Capital Employed (Equity 1.47b + L.T.Debt 601.5m))
RoIC = 6.54% (NOPAT 169.2m / Invested Capital 2.59b)
WACC = 3.57% (E(4.39b)/V(5.75b) * Re(4.40%) + D(1.36b)/V(5.75b) * Rd(1.08%) * (1-Tc(0.17)))
Discount Rate = 4.40% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 53.35 | Cagr: 0.18%
[DCF] Terminal Value 73.10% ; FCFF base≈251.3m ; Y1≈220.4m ; Y5≈178.0m
[DCF] Fair Price = 30.93 (EV 2.86b - Net Debt 1.32b = Equity 1.54b / Shares 49.8m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 99.53 | Revenue CAGR: 5.50% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=3.85 | Chg30d=-0.07% | Revisions=-62% | GrowthEPS=+2.3% | GrowthRev=+5.6%
EPS next Year (2027-12-31): EPS=4.24 | Chg30d=-0.25% | Revisions=-12% | GrowthEPS=+10.2% | GrowthRev=+3.5%
[Analyst] Revisions Ratio: -46% (up=2, down=8)